Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against X Financial, Baozun, Adamas Pharmaceuticals, and Cintas and Encourages Investors to Contact the Firm
29 janv. 2020 09h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Firm
22 janv. 2020 14h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Firm
15 janv. 2020 16h32 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Adamas Pharmaceuticals, Cintas, Correvio Pharma, and Exelon and Encourages Investors to Contact the Firm
09 janv. 2020 15h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Net 1 UEPS Technologies, X Financial, Baozun, and Adamas Pharmaceuticals and Encourages Investors to Contact the Firm
02 janv. 2020 12h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
04 juin 2019 11h49 HE
|
Schall Law
LOS ANGELES, June 04, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
31 mai 2019 11h45 HE
|
Schall Law
LOS ANGELES, May 31, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas...
Bragar Eagel & Squire, P.C. is Investigating Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on Behalf of Adamas Stockholders and Encourages Adamas Investors to Contact the Firm
28 mai 2019 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on behalf of Adamas stockholders. ...
Adamas Reports First Quarter 2019 Financial Results
09 mai 2019 16h03 HE
|
Adamas Pharmaceuticals, Inc.
- First quarter net product sales of $11.7 million - GOCOVRI® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 (GOCOVRI) in walking impairment in patients with...
Adamas to Present at Two Upcoming Investor Conferences
20 févr. 2019 16h50 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...